Amgen Inc., the Thousand Oaks-based biotechnology company, said it has received government approval for expanded use of its red blood cell-producing factor Epogen.
The drug can now be given to patients experiencing only moderate loss of red blood cells. Previously, Epogen use was restricted to patients with severe red blood cell loss.
